Overture Life has received CE Mark approval for its DaVitri platform, which automates the vitrification of unfertilized eggs. DaVitri is the first automation device with regulatory clearance for freezing unfertilized eggs in either the EU or the US, and the first freezing system approved with a validated claim for post-thaw blastocyst development rates.
The approval allows Overture Life to commercialize DaVitri in the UK, continental Europe, and Turkey. The company has raised approximately $70 million in the US.
“This is a signal that Europe understands the personal and demographic urgency of reproductive freedom,” said Overture Life CEO Hans Gangeskar. “The EU has shown its willingness to make long-term public investments in fertility infrastructure and support new technologies, and we hope to see other jurisdictions follow the same path.”
DaVitri is a tabletop device that automates vitrification of unfertilized oocytes. The system reduces operator variability, shortens training time, and delivers consistency backed by lab-verified embryo formation outcomes, according to the company.
In the US, supply bottlenecks have driven the cost of a single IVF cycle to $15,000 or more. DaVitri aims to enable egg freezing beyond throughput-constrained fertility clinics.
Overture Life’s ICSI.A robot resulted in the first two live births from an automated fertilization device in 2023. The company’s AI and metabolomics-based m|z platform for non-invasive embryo selection is accessible through a CLIA-certified laboratory in Texas.
Overture Life has R&D operations in Spain and active US operations including a CLIA-licensed laboratory. The company’s backers include Overwater Ventures, GV, Khosla Ventures, and Octopus Ventures.
